• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Lanx loses bid to toss NuVasive’s poaching lawsuit

Lanx loses bid to toss NuVasive’s poaching lawsuit

July 23, 2012 By MassDevice staff

NuVasive
Lanx

Medical device company Lanx Inc. lost a bid to have 1 of at least 2 breach-of-contract lawsuits filed against it by competitor NuVasive (NSDQ:NUVA) thrown out.

The Delaware Chancery Court denied a Lanx motion to dismiss the suit accusing it of raiding NuVasive’s sales force and poaching a surgeon consultant. A separate lawsuit filed in the U.S. District Court for Southern Texas makes similar allegations against Lanx and several named defendants, but the Delaware case names only Lanx.

That was the basis for the dismissal motion (Delaware’s chancery court rules allow defendants to move for dismissal for failure to "join an indispensable party"). But vice chancellor Sam Glasscock III denied the motion, ruling that the sales reps and surgeon in question aren’t indispensable to the case.

"The plaintiff seeks injunctive relief, as well as damages. Because that injunctive relief may affect interests of the plaintiff’s former employees, they are necessary parties to this litigation. Because in equity I may take the plaintiff’s former employees’ interests into account when considering whether to grant injunctive relief as well as the scope of any such relief, I find that the plaintiff’s former employees are not indispensable to this litigation, and the Defendant’s motion to dismiss or stay is, accordingly, denied," Glasscock wrote.

In the Texas lawsuit, filed in March, NuVasive sued 2 former sales executives, James Greene and William Vanlandingham, who jumped ship for Lanx, accusing them of violating non-compete agreements.

"On or around October, 2011, Lanx began a raid on NuVasive employees across
the country," according to the lawsuit. "This raid started in western New York, where 5 NuVasive salespeople left NuVasive to work for Lanx, and a top consulting surgeon for NuVasive announced that he had become a consultant for Lanx. Two months later, 3 top California directors and managers were recruited from NuVasive to work for Lanx. After learning of Lanx’s raid on its California employees, NuVasive sent Lanx a cease and desist letter. Lanx responded dismissively, and continued to raid NuVasive employees."

"[I]n late 2011 and early 2012, Lanx targeted NuVasive’s Texas workforce, and started recruiting Mr. Greene, Mr. Vanlandingham, and others, to join the company," according to the lawsuit, which seeks legal fees, injunctions barring further contract breaches, damages, punitive damages, and pre- and post-judgment interest.

Filed Under: Implants, Legal News, News Well, Spine Tagged With: Lanx Inc., Nuvasive

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy